Five-year heart study for Imatron (US):
This article was originally published in Clinica
Executive Summary
Imatron (US) and the University of Washington are collaborating in a new study of heart disease patients using Imatron's HeartScan coronary artery CT system to determine the degree of coronary artery calcification. The first of 160 patients with coronary artery disease and low HDL levels have undergone baseline coronary artery scans at Imatron's HeartScan-Seattle Coronary Artery Disease Risk Assessment Center. Serial scan findings will be compared with clinical and angiographic findings. Patients are to be assigned to three treatment groups, in the five-year double-blind study, to assess the magnitude and mechanism of beneficial drugs and vitamins on coronary artery disease.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.